Cipla, Appeals Govt Price Capping Waiver, Indemnity; In Advanced Talks With Moderna For Vaccine
- ByStartupStory | June 1, 2021
Cipla, appeals Govt to provide confirmation on four critical points, exemption from price restriction, indemnification, bridging trial waiver, and basic customs duty exemption. It is in advanced talks with Moderna to bring its single-dose COVID-19 vaccine to India which is why Cipla, appeals Govt to boost Moderna’s single-dose COVID-19 vaccine in India expeditiously.
Cipla, appeals Govt to provide confirmation on four critical points, exemption from price restriction, indemnification, bridging trial waiver, and basic customs duty exemption, Cipla has said such an assurance would help make this significant financial commitment of more than $1 billion (over Rs 7,250 crore) advance to Moderna for its booster vaccine in India, sources privy to the development said.
Stating that Moderna’s COVID-19 vaccine has been rated at the highest efficacy with least side effects and that the US company was also leading the development of boosters and vaccines for adolescents and paediatrics. Commending the government for its efforts to increase the vaccine availability Indian pharma giant, Cipla, appeals Govt has said its discussions with Moderna on the COVID-19 booster vaccine are nearing finalisation and for that, they are seeking the “partnership and support of the government to make this programme successful”.
Follow Startup Story
Related Posts
